(Q47392854)

15 January 2018

title

Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance (English)

1 reference

15 January 2018

0 references

0 references

0 references

2

1 reference

15 January 2018

Craig Powell

8

1 reference

15 January 2018

author name string

Louis J Aronne

1

1 reference

15 January 2018

Priscilla A Hollander

3

1 reference

15 January 2018

Richard D England

4

1 reference

15 January 2018

Solomon S Klioze

5

1 reference

15 January 2018

Robert D Chew

6

1 reference

15 January 2018

Robert J Fountaine

7

1 reference

15 January 2018

John D Obourn

9

1 reference

15 January 2018

publication date

3 February 2011

1 reference

15 January 2018

published in

Obesity

1 reference

15 January 2018

volume

19

1 reference

15 January 2018

issue

7

1 reference

15 January 2018

page(s)

1404-1414

1 reference

15 January 2018

The endocannabinoid system as a target for obesity treatment

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Endocannabinoids and the control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Leptin-regulated endocannabinoids are involved in maintaining food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

The endocannabinoid system in obesity and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Guidance for the clinical evaluation of weight-control drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Potential causes of weight gain in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.352

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2010.352

1 reference

15 January 2018

PubMed ID

21293451

1 reference

15 January 2018